Celiste, Zia .

HRN: 26-52-99  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/27/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/27/2025
02/03/2025
IVT
45mg
Q24
Sepsis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: